Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials

Authors:

Abstract
No abstract available
Funding Information
  • Novo Nordisk
  • AstraZeneca
  • AstraZeneca

This publication has 28 references indexed in Scilit: